Scientists have discovered the key factor NLRC3 which inhibits colon cancer

Immunologists at the St. Jude Children’s Research Institute in the United States recently discovered a key class of NLRC3 that inhibits colon cancer through recombinant human proteins. The research led by Thirumala-Devi Kanneganti, Ph.D., of the Department of Immunology was published in the recently published Nature journal.

In the initial experiments, the researchers found that the removal of protective NLRC3 protein increased the development of colon cancer and also confirmed the NLRC3 tumor suppressor pathway key molecules so as to protect the treatment of colon cancer mechanism and provides a new drug target. NLRC3 belongs to a class of NLR “receptor” molecules with the regulation of the immune system and other cytological functions. However, up to now, the development of NLRC3 inhibiting tumor is still unclear.

The researchers found that NLRC3 mainly play a role in colonic epithelial cells and can be directly against infection or tumor cell development caused by intestinal inflammatory response. “All of these experimental designs are complementary and can further help us to confirm the function of NLRC3, which is essential for protecting the body from the proliferation of abnormal cells.” When the NLRC3 gene is missing, the tumor will develop “Suggests Kanneganti”. This suggests that if we can find a way to clinically induce high expression of NLRC3, we can block the signaling pathways leading to tumorigenesis,” Kanneganti said.

“The most important thing to improve the activity of the NLRC3 molecule is to precisely determine the signaling pathways and mechanisms involved in the regulation of this molecule in the cell,” says Kanneganti. The researchers revealed that NLRC3 plays a “brake” role in the PI3K-mTOR pathway, which usually starts early in the development of the tumor. “The development of direct drug therapy for the PI3K-mTOR pathway is very difficult because the pathway is central to cell signaling,” says Kanneganti. “Therefore, we can target the NLRC3 molecule itself to block early development of tumor cells.”

Despite the preliminary clarity of the mechanism of action, the team believes that the role of NLRC3 not only to prevent the occurrence and development of tumors in some infectious and inflammatory diseases, there should still be a lot we don’t know about the role. From a broader perspective, further in-depth study could elucidate the function of other NLR family members. “NLR family functions are diverse. They not only can regulate the immune system and inflammatory response, but also can block the tumor production process,” Professor Kanneganti said, “No one would link NLR family protein and PI3K-mTOR pathway together previously, so this study makes people particularly excited, because it is likely to open a new door to studying the functions of NLR.” Flarebio provides superior recombinant proteins including recombinant Ece1 at great prices.